Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Vitamin E, specifically in the form of alpha-tocopherol, has been investigated for its potential benefits in treating hepatitis, particularly non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD). Several randomized controlled trials and meta-analyses suggest that Vitamin E supplementation can improve liver histology in patients with NASH who do not have diabetes. The proposed mechanism involves Vitamin E’s antioxidant properties, which help mitigate oxidative stress believed to contribute to hepatocyte injury and inflammation in chronic liver diseases.

For example, the PIVENS trial (Sanyal et al., NEJM 2010) demonstrated that non-diabetic adults with NASH receiving 800 IU/day of Vitamin E for 96 weeks had significant improvements in liver histology compared to placebo. However, the evidence is more limited in other types of hepatitis, such as hepatitis B or C, where Vitamin E has not shown consistent benefit. Clinical guidelines (AASLD, EASL) cautiously recommend Vitamin E for non-diabetic adults with biopsy-proven NASH but do not support its use for viral hepatitis.

There are also concerns about long-term, high-dose Vitamin E supplementation due to potential adverse effects, including increased all-cause mortality at very high doses. Regarding alpha-tocomonoenol specifically, this is a less common form of Vitamin E compared to alpha-tocopherol, and there is limited direct research on its effects in hepatitis. Overall, the use of Vitamin E is supported by moderate scientific evidence in NASH but not other forms of hepatitis, and use should be based on clinical context.

More about Vitamin E (Alpha-Tocomonoenol)
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Vitamin E (Alpha-Tocomonoenol)

Products containing Vitamin E (Alpha-Tocomonoenol)